COMMUNIQUÉS West-GlobeNewswire

Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA
07/03/2019
Well-Validated, Pre-Clinical Success Shown in the Reduction of Alpha-Synuclein New Compound Expands Seelos’ Parkinson's Portfolio NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a [...]
Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
07/03/2019
DUBLIN, Ireland, March 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live [...]
Neos Therapeutics to Host Fourth Quarter and Year-End 2018 Financial and Operating Results Conference Call on March 14th, 2019
07/03/2019
DALLAS and FORT WORTH, Texas, March 07, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR [...]
Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
07/03/2019
PDUFA Target Action Date of October 20th, 2019 REHOVOT, Israel, and BRIDGEWATER, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company [...]
AMAG Pharmaceuticals Presents New Data on Bremelanotide and Hypoactive Sexual Desire Disorder at the ISSWSH/ISSM Joint Meeting
07/03/2019
WALTHAM, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that new and encore data related to bremelanotide and Hypoactive Sexual Desire Disorder (HSDD) will be [...]
TYME Continues to Expand Pipeline of Cancer Metabolism-Based Therapies to Potentially Benefit Patients with Difficult-to-Treat Cancers
07/03/2019
Targeting IND-enabling program for TYME-18 in 2H2019 NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies ( [...]
Aduro Biotech to Present at Two Upcoming Investor Conferences in March
07/03/2019
BERKELEY, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Aduro management is scheduled to present at the following investor conferences: 39 th Annual Cowen Health Care [...]
Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference
07/03/2019
BOSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
Samumed to Present Clinical Data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
07/03/2019
SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that clinical data from its successful phase 2a trial of SM04690 for the treatment of knee osteoarthritis (OA) has been accepted as a poster [...]
BioSig Technologies to Present at the 31st Annual ROTH Conference
07/03/2019
Santa Monica, CA, March 07, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed [...]
LIDDS: Collaboration with Belina Pharma concludes
07/03/2019
A collaboration agreement with Belina was signed in 2017 with the aim of using LIDDS depot technology in combination with a drug intended for the treatment of breast cancer. The collaboration has now concluded. LIDDS [...]
Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity
07/03/2019
– Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716 advancing into two Phase 2 trials in 1H 2019 [...]
Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update
07/03/2019
- A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout - - Plan to initiate second A4250 pivotal program in biliary atresia - - Plan to initiate Phase 2 study with elobixibat in NASH [...]
Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting
07/03/2019
Company will present two posters on CNTX-4975 for treatment of moderate to severe knee osteoarthritis pain; pharmacological data from preclinical and Phase 1 and 2 clinical trials describing the mechanism of action; and [...]
XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights
07/03/2019
Added seven new partner-funded programs in 2018 with potential for milestone and royalty payments Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., March 07, 2019 (GLOBE NEWSWIRE [...]
Ossur Hf : Board decisions following the Annual General Meeting
07/03/2019
Announcement no. 17/2019 7 March 2019 Board decisions following the Annual General Meeting Enclosed are the Board decisions following the Annual General Meeting of Össur hf. held today, Thursday 7 March 2019. Further [...]
Inivata Publishes Positive Results of Clinical Validation and Utility Study for InVision® Liquid Biopsy Test
07/03/2019
Inivata Publishes Positive Results of Clinical Validation and Utility Study for InVision ® Liquid Biopsy Test Large, real-world, prospective study shows Inivata’s liquid biopsy test is able to provide molecular profile [...]
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
07/03/2019
WALTHAM, Mass. and CRESTWOOD, Ky., March 07, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Emerald Health Therapeutics’ Licensed Endo Product Wins Taste For Life’s 2019 Essentials Supplement Award in the U.S.
07/03/2019
Novel Emerald endocannabinoid-supporting products well-positioned to develop brand presence and market demand among both cannabis and non-cannabis users SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Emerald Health [...]

Pages